dc.contributor.author | Nome, Ragnhild Veline | |
dc.contributor.author | Småstuen, Milada Cvancarova | |
dc.contributor.author | Bjøro, Trine | |
dc.contributor.author | Kiserud, Cecilie E. | |
dc.contributor.author | Fosså, Sophie Dorothea | |
dc.date.accessioned | 2020-11-06T13:24:05Z | |
dc.date.accessioned | 2021-02-09T15:23:05Z | |
dc.date.available | 2020-11-06T13:24:05Z | |
dc.date.available | 2021-02-09T15:23:05Z | |
dc.date.issued | 2020-02-11 | |
dc.identifier.citation | Nome, Småstuen, Bjøro, Kiserud, Fosså. Longitudinal kidney function outcome in aging testicular cancer survivors. Acta Oncologica. 2020;59(4):467-474 | en |
dc.identifier.issn | 0284-186X | |
dc.identifier.issn | 1651-226X | |
dc.identifier.uri | https://hdl.handle.net/10642/9489 | |
dc.description.abstract | Purpose: Testicular cancer survivors (TCSs) have increased risk of reduced kidney function related to
treatment burden, but longitudinal studies of renal outcome in aging TCSs have been lacking. This
longitudinal study describes age- and treatment-related kidney function changes in TCSs compared to
a comparison group from the general population.
Patients and methods: Estimated glomerular filtration rate (eGFR) was determined in blood samples
from Norwegian TCSs (diagnosed 1980–1994) and surveyed median 11, 19 and 26 years since diagnosis (Survey1 [N ¼ 1273], 2 [N ¼ 849] and 3 [N ¼ 670]) defining four treatment groups; Surgery only,
Radiotherapy (RT) only, Cisplatin-based chemotherapy (CBCT) 850 mg and High CBCT/RT >850 mg
cisplatin or any combination of CBCT with RT. A comparison group was constructed from similarly
aged men who participated in a population-based health survey. By multiple linear regressions and
generalized mixed models for repeated measurements, we studied difference in eGFR between TCSs
and the comparison group for all TCSs combined and stratified by treatment modality.
Results: At Survey 1, the kidney function for the youngest TCSs combined versus the comparison
group was significantly reduced by mean six units (mL/min/1.73 m2
) with further decline to mean 12
units at Survey 3. The kidney function was significantly reduced in all treatment groups with the largest differences emerging for TCSs from the High CBCT/RT Group, thus indicating a deteriorating
impact of high cumulative doses of cisplatin.
Conclusion: Collated to the comparison group, the kidney function in TCSs became increasingly
impaired during nearly three post-treatment decades, related to the treatment modality. Early detection and intervention of kidney dysfunction is important to reduce the risk of TCSs’ long-term morbidity and mortality related to nephrotoxicity, such as cardio-vascular diseases. | en |
dc.language.iso | en | en |
dc.publisher | Taylor & Francis | en |
dc.relation.ispartofseries | Acta Oncologica;Volume 59, 2020 - Issue 4 | |
dc.rights | Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License | en |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.subject | Kidney function outcomes | en |
dc.subject | Testicular cancer survivors | en |
dc.subject | Treatment burdens | en |
dc.subject | Impaired kidney functions | en |
dc.subject | Age-related kidney function changes | en |
dc.subject | Treatment-related kidney function changes | en |
dc.title | Longitudinal kidney function outcome in aging testicular cancer survivors | en |
dc.type | Journal article | |
dc.type | Peer reviewed | en |
dc.date.updated | 2020-11-06T13:24:05Z | |
dc.description.version | publishedVersion | en |
dc.identifier.cristin | 1840918 | |
dc.source.journal | Acta Oncologica | |